The role of nitric oxide in multiple sclerosis

Lancet Neurology

Volumn 1, Issue 4, 2002, Pages 232-241

  Smith, Kenneth J ^a   Lassmann, Hans ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; SCAVENGER;

ASTROCYTE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CLINICAL FEATURE; CONCENTRATION RESPONSE; DISEASE COURSE; ENCEPHALOMYELITIS; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; REVIEW; DRUG EFFECT; IMMUNE SYSTEM; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

FREE RADICAL SCAVENGERS; HUMANS; IMMUNE SYSTEM; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NITRIC OXIDE;

EID: 0013292906     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00102-3     Document Type: Review

References (150)

1. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine. 3rd edn :1998;Oxford University Press, Oxford.
2. Hogg N. The biochemistry and physiology of S-nitrosothiols. Annu Rev Pharmacol Toxicol. 42:2002;585-600.
3. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol. 271:1996;C1424-C1437.
4. Smith K.J., Kapoor R., Felts P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 9:1999;69-92.
5. Crow J.P., Beckman J.S. The importance of superoxide in nitric oxide-dependent toxicity: evidence for peroxynitrite-mediated injury. Adv Exp Med Biol. 387:1996;147-161.
6. Lin R.F., Lin T.S., Tilton R.G., Cross A.H. Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study. J Exp Med. 178:1993;643-648.
7. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J. 357:2001;593-615.
8. Koprowski H., Zheng Y.M., Heber-Katz E., et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA. 90:1993;3024-3027.
9. van Dam A.M., Bauer J., Man-A-Hing W.K., Marquette C., Tilders F.J.B.F. Appearance of inducible nitric oxide synthase in the rat central nervous system after rabies virus infection and during experimental allergic encephalomyelitis but not after peripheral administration of endotoxin. J Neurosci Res. 40:1995;251-260.
10. Cross A.H., Manning P.T., Stern M.K., Misko T.P. Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J Neuroimmunol. 80:1997;121-130.
11. Okuda Y., Nakatsuji Y., Fujimura H., et al. Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J Neuroimmunol. 62:1995;103-112.
12. Bitsch A., Wegener C., Da Costa C., et al. Lesion development in Marburg's type of acute multiple sclerosis: from inflammation to demyelination. Mult Scler. 5:1999;138-146.
13. Bagasra O., Michaels F.H., Zheng Y.M., et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA. 92:1995;12041-12045.
14. Bo L., Dawson T.M., Wesselingh S., et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol. 36:1994;778-786.
15. Oleszak E.L., Zaczynska E., Bhattacharjee M., Butunoi C., Legido A., Katsetos C.D. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol. 5:1998;438-445.
16. Liu J.S., Zhao M.L., Brosnan C.F., Lee S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol. 158:2001;2057-2066.
17. De Groot C.J., Ruuls S.R., Theeuwes J.W., Dijkstra C.D., van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol. 56:1997;10-20.
18. Hooper D.C., Bagasra O., Marini J.C., et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA. 94:1997;2528-2533.
19. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.E., Misko T.P. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol. 88:1998;45-56.
20. Ikeda M., Sato I., Matsunaga T., Takahashi M., Yuasa T., Murota S. Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barré syndrome. Intern Med. 34:1995;734-737.
21. De Bustos F., Navarro J.A., de Andres C., et al. Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol. 41:1999;44-47.
22. Brundin L., Morcos E., Olsson T., Wiklund N.P., Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol. 6:1999;585-590.
23. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler. 4:1998;27-30.
24. Johnson A.W., Land J.M., Thompson E.J., Bolanos J.P., Clark J.B., Heales S.J. Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry. 58:1995;107.
25. Peltola J., Ukkonen M., Moilanen E., Elovaara I. Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy. Neurology. 57:2001;895-896.
26. 3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci. 153:1997;32-34.
27. Svenningsson A., Petersson A.-S., Andersen O., Hansson G.K. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology. 53:1999;1880-1882.
28. Xiao B-G., Zhang G.-X., Ma C.-G., Link H. The cerebrospinal fluid from patients with multiple sclerosis promotes neuronal and oligodendrocyte damage by delayed production of nitric oxide in vitro. J Neurol Sci. 142:1996;114-120.
29. Zabaleta M.E., Bianco N.E., De Sanctis J.B. Serum nitric oxide products in patients with multiple sclerosis: relationship with clinical activity. Med Sci Res. 26:1998;373-374.
30. Giovannoni G., Heales S.J., Silver N.C., et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci. 145:1997;77-81.
31. Zabaleta M.E., Bianco N.E., De Sanctis J.B. Serum nitrotyrosine levels in patients with multiple sclerosis: relationship with clinical activity. Med Sci Res. 26:1998;407-408.
32. O'Brien N.C., Charlton B., Cowden W.B., Willenborg D.O. Nitric oxide plays a critical role in the recovery of lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction. J Immunol. 163:1999;6841-6847.
33. Boullerne A.I., Petry K.G., Meynard M., Geffard M. Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J Neuroimmunol. 60:1995;117-124.
34. Giovannoni G., Silver N.C., O'Riordan J., et al. Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease. Mult Scler. 5:1999;335-341.
35. Lassmann H. Pathology of multiple sclerosis. Compston A. McAlpine's multiple sclerosis. 3rd edn :1998;323-358 Churchill Livingstone, London.
36. Gay F.W., Drye T.J., Dick G.W., Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion. Brain. 120:1997;1461-1483.
37. Kermode A.G., Thompson A.J., Tofts P., et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain. 113:1990;1477-1489.
38. Kermode A.G., Tofts P.S., Thompson A.J., et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology. 40:1990;229-235.
39. Kwon E.E., Prineas J.W. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions: an immunohistochemical study. J Neuropathol Exp Neurol. 53:1994;625-636.
40. Kornek B., Lassmann H. Axonal pathology in multiple sclerosis: a historical note. Brain Pathol. 9:1999;651-656.
41. Prineas J.W., Kwon E.E., Goldenberg P.Z., et al. Multiple sclerosis: oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest. 61:1989;489-503.
42. Prineas J.W., Barnard R.O., Kwon E.E., Sharer L.R., Cho E.S. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol. 33:1993;137-151.
43. Rand M.J. Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission. Clin Exp Pharmacol Physiol. 19:1992;147-169.
44. Toda N., Tanaka T., Ayajiki K., Okamura T. Cerebral vasodilatation induced by stimulation of the pterygopalatine ganglion and greater petrosal nerve in anesthetized monkeys. Neuroscience. 96:2000;393-398.
45. Brian J.E., Faraci F.M. Tumor necrosis factor-alpha-induced dilatation of cerebral arterioles. Stroke. 29:1998;509-515.
46. Kobari M., Fukuuchi Y., Tomita M., et al. Transient cerebral vasodilatory effect of neuropeptide Y mediated by nitric oxide. Brain Res Bull. 31:1993;443-448.
47. Faraci F.M., Breese K.R. Nitric oxide mediates vasodilatation in response to activation of N-methyl-D-aspartate receptors in brain. Circ Res. 72:1993;476-480.
48. Brian J.E., Faraci F.M., Heistad D.D. Recent insights into the regulation of cerebral circulation. Clin Exp Pharmacol Physiol. 23:1996;449-457.
49. Youl B.D., Turano G., Miller D.H., et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain. 114:1991;2437-2450.
50. Hurst R.D., Fritz I.B. Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier. J Cell Physiol. 167:1996;89-94.
51. Shukla A., Dikshit M., Srimal R.C. Nitric oxide-dependent blood-brain barrier permeability alteration in the rat brain. Experientia. 52:1996;136-140.
52. Mayhan W.G. Nitric oxide donor-induced increase in permeability of the blood-brain barrier. Brain Res. 866:2000;101-108.
53. Thiel V.E., Audus K.L. Nitric oxide and blood-brain barrier integrity. Antioxid Redox Signal. 3:2001;273-278.
54. Winkler F., Koedel U., Kastenbauer S., Pfister H.W. Differential expression of nitric oxide synthases in bacterial meningitis: role of the inducible isoform for blood-brain barrier breakdown. J Infect Dis. 183:2001;1749-1759.
55. Boje K.M.K., Lakhman S.S. Nitric oxide redox species exert differential permeability effects on the blood-brain barrier. J Pharmacol Exp Ther. 293:2000;545-550.
56. Mayhan W.G. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am J Physiol. 276:1999; C1148-C1153.
57. Janigro D., West G.A., Nguyen T.S., Winn H.R. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ Res. 75:1994;528-538.
58. Kean R.B., Spitsin S.V., Mikheeva T., Scott G.S., Hooper D.C. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol. 165:2000;6511-6518.
59. Hurst R.D., Clark J.B. Nitric oxide-induced blood-brain barrier dysfunction is not mediated by inhibition of mitochondrial respiratory chain activity and/or energy depletion. Nitric Oxide. 1:1997;121-129.
60. Blais V., Rivest S. Inhibitory action of nitric oxide on circulating tumor necrosis factor-induced NF-kappaB activity and COX-2 transcription in the endothelium of the brain capillaries. J Neuropathol Exp Neurol. 60:2001;893-905.
61. Wekerle H. Immunology of multiple sclerosis. Compston A. McAlpine's multiple sclerosis. 3rd edn :1998;379-408 Churchill Livingstone, London.
62. Wekerle H., Linington C., Lassmann H., Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci. 9:1986;271-277.
63. Hickey W.F. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1:1991;97-105.
64. Trebst C., Ransohoff R.M. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol. 58:2001;1975-1980.
65. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 37:1995;424-435.
66. Flugel A., Berkowicz T., Ritter T., et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity. 14:2001;547-560.
67. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol. 143:1993;446-452.
68. Pender M.P., Nguyen K.B., McCombe P.A., Kerr J.F. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci. 104:1991;81-87.
69. Bauer J., Bradl M., Hickey W.F., et al. T-cell apoptosis in inflammatory brain lesions: Destruction of T cells does not depend on antigen recognition. Am J Pathol. 153:1998;715-724.
70. Gold D.P., Shroeder K., Golding A., Brostoff S.W., Wilson D.B. T-cell receptor peptides as immunotherapy for autoimmune disease. Crit Rev Immunol. 17:1997;507-510.
71. Sicher S.C., Vazquez M.A., Lu C.Y. Inhibition of macrophage Ia expression by nitric oxide. J Immunol. 153:1994;1293-1300.
72. Albina J.E., Henry W.L. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J Surg Res. 50:1991;403-409.
73. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 88:1991;4651-4655.
74. Berger T., Weerth S., Kojima K., Linington C., Wokerle H., Lassmann H. Experimental autoimmune encephalomyelitis: The antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest. 76:1997;355-364.
75. Okuda Y., Sakoda S., Fujimura H., Yanagihara T. Nitric oxide via an inducible isoform of nitric oxide synthase is a possible factor to eliminate inflammatory cells from the central nervous system of mice with experimental allergic encephalomyelitis. J Neuroimmunol. 73:1997;107-116.
76. Zettl U.K., Mix E., Zielasek J., Stangel M., Hartung H.P., Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol. 178:1997;1-8.
77. Bachmann R., Eugster H.P., Frei K., Fontana A., Lassmann H. Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol. 154:1999;1417-1422.
78. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain. 122:1999;2279-2295.
79. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 47:2000;707-717.
80. Mitrovic B., Ignarro L.J., Montestruque S., Smoll A., Merrill J.E. Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience. 61:1994;575-585.
81. Mitrovic B., Ignarro L.J., Vinters H.V., et al. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience. 65:1995;531-539.
82. Boullerne A.I., Nedelkoska L., Benjamins J.A. Synergism of nitric oxide and iron in killing the transformed murine oligodendrocyte cell line N20.1. J Neurochem. 72:1999;1050-1060.
83. Garthwaite G., Goodwin A.M., Batchelor K., Leeming K., Garthwaite J. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience. 109:2002;145-155.
84. Molina-Holgado E., Vela J.M., Arevalo-Martin A., Guaza C. LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur J Neurosci. 13:2001;493-502.
85. Mackenzie-Graham A.J., Mitrovic B., Smoll A., Merrill J.E. Differential sensitivity to nitric oxide in immortalized, cloned murine oligodendrocyte cell lines. Dev Neurosci. 16:1994;162-171.
86. Zhang J., Dawson V.L., Dawson T.M., Snyder S.H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 263:1994;687-689.
87. Maeda H., Okamoto T., Akaike T. Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals. Biol Chem. 379:1998;193-200.
88. van der Veen R.C., Roberts L.J. Contrasting roles for nitric oxide and peroxynitrite in the peroxidation of myelin lipids. J Neuroimmunol. 95:1999;1-7.
89. Graham A., Hogg N., Kalyanaraman B., O'Leary V., Darley-Usmar V., Moncada S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 330:1993;181-185.
90. van der Laan L.J., Ruuls S.R., Weber K.S., Lodder I.J., Dopp E.A., Dijkstra C.D. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J Neuroimmunol. 70:1996;145-152.
91. Arnett H.A., Hellendall R.P., Matsushima G.K., et al. The protective role of nitric oxide in a neurotoxicant-induced demyelinating model. J Immunol. 168:2002;427-433.
92. Smith K.J., McDonald W.I. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci. 354:1999;1649-1673.
93. Moreau T., Coles A., Wing M., et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 119:1996;225-237.
94. Coles A.J., Wing M.G., Molyneux P., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 46:1999;296-304.
95. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 120:1997;2149-2157.
96. Shrager P., Custer A.W., Kazarinova K., Rasband M.N., Mattson D. Nerve conduction block by nitric oxide that is mediated by the axonal environment. J Neurophysiol. 79:1998;529-536.
97. Ahern G.P., Hsu S.-F., Klyachko V.A., Jackson M.B. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J Biol Chem. 275:2000;28810-28815.
98. Li Z., Chapleau M.W., Bates J.N., Bielefeldt K., Lee H.-C., Abboud F.M. Nitric oxide as an autocrine regulator of sodium currents in baroreceptor neurons. Neuron. 20:1998;1039-1049.
99. + conductance in identified neurons of Aplysia. Brain Res. 670:1995;248-256.
100. + currents in axotomized C- type DRG neurons. J Neurophysiol. 83:2000;2431-2442.
101. Renganathan M., Cummins T.R., Waxman S.G. Nitric oxide blocks fast, slow and persistent sodium currents in C-type DRG neurons by a cGMP-independent mechanism. J Neurophysiol. 87:2002;761-775.
102. Liu Q.-S., Jia Y.-S., Ju G. Nitric oxide inhibits neuronal activity in the supraoptic nucleus of the rat hypothalamic slices. Brain Res Bull. 43:1997;121-125.
103. Shrager P. Slow sodium inactivation in nerve after exposure to sulfhydryl blocking reagents. J Gen Physiol. 69:1977;183-202.
104. Kurenny D.E., Moroz L.L., Turner R.W., Sharkey K.A., Barnes S. Modulation of ion channels in rod photoreceptors by nitric oxide. Neuron. 13:1994;315-324.
105. Kornek B., Storch M.K., Bauer J., et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain. 124:2001;1114-1124.
106. Bains J.S., Ferguson A.V. Nitric oxide depolarizes type II paraventricular nucleus neurons in vitro. Neuroscience. 79:1997;149-159.
107. Guzman N.J., Fang M.Z., Tang S.S., Ingelfinger J.R., Garg L.C. Autocrine inhibition of Na+/K(+)-ATPase by nitric oxide in mouse proximal tubule epithelial cells. J Clin Invest. 95:1995;2083-2088.
108. Jeffrey D.R., Absher J., Pfeiffer F.E., Jackson H. Cortical deficits in multiple sclerosis on the basis of subcortical lesions. Mult Scler. 6:2000;50-55.
109. Holscher C. Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Trends Neurosci. 20:1997;298-303.
110. Kidd D., Barkhof F., McConnell R., Algra P.R., Allen I.V., Revesz T. Cortical lesions in multiple sclerosis. Brain. 122:1999;17-26.
111. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 50:2001;389-400.
112. Choi Y.B., Lipton S.A. Redox modulation of the NMDA receptor. Cell Mol Life Sci. 57:2000;1535-1541.
113. Strijbos P.J., Leach M.J., Garthwaite J. Vicious cycle involving Na+ channels, glutamate release, and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation. J Neurosci. 16:1996;5004-5013.
114. Smith T., Groom A., Zhu B., Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med. 6:2000;62-66.
115. Werner P., Pitt D., Raine C.S. Glutamate excitotoxicity: a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis? J Neural Transm Suppl. 60:2000;375-385.
116. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338:1998;278-285.
117. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain. 120:1997;393-399.
118. Kornek B., Storch M.K., Weissert R., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 157:2000;267-276.
119. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Bruck W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain. 123:2000;1174-1183.
120. Prineas J.W., Wright R.G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest. 38:1978;409-421.
121. Stys P.K., LoPachin R.M. Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons. Neuroscience. 82:1998;21-32.
122. Waxman S.G., Black J.A., Ransom B.R., Stys P.K. Anoxic injury of rat optic nerve: ultrastructural evidence for coupling between Na+ influx and Ca(2+)-mediated injury in myelinated CNS axons. Brain Res. 644:1994;197-204.
123. Ransom B.R., Waxman S.G., Stys P.K. Anoxic injury of central myelinated axons: ionic mechanisms and pharmacology. Res Publ Assoc Res Nerv Ment Dis. 71:1993;121-151.
124. Smith K.J., Kapoor R., Hall S.M., Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol. 49:2001;470-476.
125. Brorson J.R., Schumacker P.T., Zhang H. Nitric oxide acutely inhibits neuronal energy production. J Neurosci. 19:1999;147-158.
126. Bolanos J.P., Almeida A., Stewart V., et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem. 68:1997;2227-2240.
127. Kapoor R., Davies M., Smith K.J. Temporary axonal conduction block and axonal loss in inflammatory neurological disease: a potential role for nitric oxide? Ann N Y Acad Sci. 893:1999;304-308.
128. Smith K.J., Blaker P.A., Kapoor R., Hall S.M., Davies M. Protection of axons from degeneration resulting from exposure to nitric oxide. J Neurol Neurosurg Psychiatry. 70:2001;282.
129. Anthony D.C., Miller K.M., Fearn S., et al. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol. 87:1998;62-72.
130. Lumsden C.E. The neuropathology of multiple sclerosis. Vinken P.J., Bruyn G.W. Handbook of clinical neurology. 1970;217-309 Elsevier, Amsterdam.
131. Lipton S.A. Neuronal protection and destruction by NO. Cell Death Differ. 6:1999;943-951.
132. Bonfoco E., Krainc D., Ankarcrona M., Nicotera P., Lipton S.A. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D- aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA. 92:1995;7162-7166.
133. Nomura Y., Uehara T., Nakazawa M. Neuronal apoptosis by glial NO: involvement of inhibition of glyceraldehyde-3-phosphate dehydrogenase. Hum Cell. 9:1996;205-214.
134. Estevez A.G., Spear N., Manuel S.M., et al. Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J Neurosci. 18:1998;923-931.
135. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23:2000;298-304.
136. Zhao W., Tilton R.G., Corbett J.A., et al. Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J Neuroimmunol. 64:1996;123-133.
137. Cowden W.B., Cullen F.A., Staykova M.A., Willenborg D.O. Nitric oxide is a potential down-regulating molecule in autoimmune disease: inhibition of nitric oxide production renders PVG rats highly susceptible to EAE. J Neuroimmunol. 88:1998;1-8.
138. Okuda Y., Sakoda S., Fujimura H., Yanagihara T. Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experimental allergic encephalomyelitis in the induction and progression phase. J Neuroimmunol. 81:1998;201-210.
139. Sahrbacher U.C., Lechner F., Eugster H.-P., Frei K., Lassmann H., Fontana A. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur J Immunol. 28:1998;1332-1338.
140. Thillaye-Goldenberg B., Goureau O., Naud M.C., deKozak Y. Delayed onset and decreased severity of experimental autoimmune uveoretinitis in mice lacking nitric oxide synthase type 2. J Neuroimmunol. 110:2000;31-44.
141. Zielasek J., Jung S., Gold R., Liew F.Y., Toyka K.V., Hartung H.P. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 58:1995;81-88.
142. Willenborg D.O., Staykova M.A., Cowden W.B. Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: A review. J Neuroimmunol. 100:1999;21-35.
143. Singh V.K., Mehrotra S., Narayan P., Pandey C.M., Agarwal S.S. Modulation of autoimmune diseases by nitric oxide. Immunol Res. 22:2000;1-19.
144. Sommer N., Loschmann P.A., Northoff G.H., et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1:1995;244-248.
145. Martinez I., Puerta C., Redondo C., Garcia-Merino A. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: Sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase. J Neurol Sci. 164:1999;13-23.
146. Xiao B.-G., Bail X.-F., Zhang G.-X., Hedlund G., Link H. Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells. Neurosci Lett. 249:1998;17-20.
147. Hooper D.C., Spitsin S., Kean R.B., et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA. 95:1998;675-680.
148. Kim Y.S., Kim S.U. Oligodendroglial cell death induced by oxygen radicals and its protection by catalase. J Neurosci Res. 29:1991;100-106.
149. Noble P.G., Antel J.P., Yong V.W. Astrocytes and catalase prevent the toxicity of catecholamines to oligodendrocytes. Brain Res. 633:1994;83-90.
150. Hua L.L., Liu J.S.H., Brosnan C.F., Lee S.C. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: implications for multiple sclerosis. Ann Neurol. 43:1998;384-387.